Ischemic Heart Disease: Special Considerations in Cardio-Oncology

Dana Elena Giza,Fernando Boccalandro,Juan Lopez-Mattei,Gloria Iliescu,Kaveh Karimzad,Peter Kim,Cezar Iliescu
DOI: https://doi.org/10.1007/s11936-017-0535-5
2017-04-19
Current Treatment Options in Cardiovascular Medicine
Abstract:Opinion statementThe interplay and balance between the competing morbidity and mortality of cardiovascular diseases and cancer have a significant impact on both short- and long-term health outcomes of patients who survived cancer or are being treated for cancer. Ischemic heart disease in patients with cancer or caused by cancer therapy is a clinical problem of emerging importance. Prompt recognition and optimum management of ischemic heart disease mean that patients with cancer can successfully receive therapies to treat their malignancy and reduce morbidity and mortality due to cardiovascular disease. In this sense, the presence of cancer and cancer-related comorbidities (e.g., thrombocytopenia, propensity to bleed, thrombotic status) substantially complicates the management of cardiovascular diseases in cancer patients. In this review, we will summarize the current state of knowledge on the management strategies for ischemic disease in patients with cancer, focusing on the challenges encountered when addressing these complexities.
What problem does this paper attempt to address?